Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2025)

Telix Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 2 years, most recently at $44.7 million for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability rose 628.73% to $44.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.7 million through Dec 2025, up 628.73% year-over-year, with the annual reading at $44.7 million for FY2025, 671.33% up from the prior year.
  • Non-Current Deferred Tax Liability was $44.7 million for Q4 2025 at Telix Pharmaceuticals, up from $6.1 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $44.7 million in Q4 2025 and troughed at $6.1 million in Q4 2024.